1 Faculty of Medicine, University of Toronto, ON, Canada.
2 Division of Dermatology, Department of Medicine, University of Toronto, ON, Canada.
J Cutan Med Surg. 2019 Jul/Aug;23(4):442-448. doi: 10.1177/1203475419847950. Epub 2019 May 3.
Pimecrolimus is a topical calcineurin inhibitor currently approved for second-line use in the management of mild-to-moderate atopic dermatitis in patients age 2 years and older. Given the safety profile and nonsteroidal mechanism of pimecrolimus, there has been significant interest in its use in the treatment of a variety of dermatological conditions. This article reviews research that has been published on the off-label uses of topical pimecrolimus, with a focus on published RCTs. Convincing evidence exists supporting pimecrolimus' efficacy in oral lichen planus and seborrheic dermatitis. For other conditions studied to date, pimecrolimus may prove to be a useful treatment alternative when conventional agents fail. Adverse events seen with its off-label use were typically application site reactions, the most common being a transient burning sensation. In summary, pimecrolimus appears to be an effective agent in the treatment of multiple dermatological conditions and may be worth considering as a pharmacologic alternative in several conditions when first-line treatment fails, or for areas that are more susceptible to the adverse effects of topical corticosteroids.
吡美莫司是一种局部钙调磷酸酶抑制剂，目前已获准用于 2 岁及以上轻至中度特应性皮炎患者的二线治疗。鉴于吡美莫司的安全性和非甾体机制，人们对其在治疗各种皮肤病方面的应用产生了浓厚的兴趣。本文综述了关于局部吡美莫司的标签外用途的研究，重点是已发表的随机对照试验。有令人信服的证据支持吡美莫司在口腔扁平苔藓和脂溢性皮炎中的疗效。对于迄今为止研究过的其他疾病，当常规药物治疗失败时，吡美莫司可能被证明是一种有用的治疗选择。其标签外使用的不良反应通常为局部用药反应，最常见的是短暂烧灼感。总之，吡美莫司似乎是一种有效的治疗多种皮肤病的药物，当一线治疗失败时，或在对局部皮质类固醇不良反应更敏感的区域，它可能是几种疾病的药物治疗的另一种选择。
